PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 27, 2026RMD Open0 citationsOpen Access

Long-Term Osteoprotective Effects of IL-17A Blockade in Psoriatic Arthritis

Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLouis SchusterATAlp TemizMMMelek Yalcin Mutlu

Discussion

Loading...

Member takes

Overview

Phase-IV study evaluates long-term bone health and clinical outcomes in psoriatic arthritis patients treated with secukinumab, indicating sustained benefits.

Key Points

  • This research aims to assess the long-term effects of secukinumab on bone structure and clinical outcomes in psoriatic arthritis.
  • Conducted a phase-IV non-interventional study on adult patients with active psoriatic arthritis.
  • Used high-resolution peripheral quantitative CT (HR-pQCT) and MRI to evaluate bone changes over 48 months.
  • All patients received secukinumab treatment and were followed according to clinical practice.
  • Assessed bone density, erosions, and inflammatory changes using specific scoring systems.
  • 68.8% drug survival rate at 48 months.
  • Significant clinical improvements across various measures of disease activity and functional status.
  • Bone density and microarchitecture remained stable with no significant progression of erosions.
  • Inflammatory changes on MRI remained low, suggesting effective long-term management.

Cite This Study

Schuster et al. (2026) studied this question.

synapsesocial.com/papers/69a13591ed1d949a99abf88chttps://doi.org/10.1136/rmdopen-2025-005857
View Full Paper
Ask AI
Bookmark
Share